Last reviewed · How we verify
V110
V110 is a small molecule that inhibits the activity of a specific enzyme.
V110 is a small molecule that inhibits the activity of a specific enzyme. Used for Type 2 diabetes.
At a glance
| Generic name | V110 |
|---|---|
| Also known as | PNEUMOVAX™23, 23-Valent Pneumococcal Polysaccharide Vaccine |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting this enzyme, V110 aims to reduce the production of a certain compound that contributes to disease progression. This mechanism is being explored in the treatment of a specific condition.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy (PHASE1, PHASE2)
- Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (PHASE3)
- Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) (PHASE4)
- A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018) (PHASE3)
- Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) (PHASE3)
- Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) (PHASE3)
- A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V110 CI brief — competitive landscape report
- V110 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI